ARL6IP4

Across TCGA pan-cancer cohorts, ARL6IP4 Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated ARL6IP4 data layer compared with 22 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher ARL6IP4 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARL6IP4 expression acts as an unfavorable survival marker.

LUSC are the cancer types where ARL6IP4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUSC	DFS	Median	All	0.231	0.758	.017	18	view →

Pink = unfavorable, green = favorable. Showing the 1 strongest of 1 lineages.

ARL6IP4–LUSC (DFS)

Open the LUSC breakdown →